CPA
RIGL icon

Capital Performance Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Capital Performance Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$32 – 2123
2024
Q3 		$32 Buy
+2
New +$24 ﹤0.01% 2834

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Performance Advisors's RIGL Position: Q4 2024 in Review

Capital Performance Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q4 2024, closing a stake of 2 shares — an estimated $32 sold.

Capital Performance Advisors first reported a position in RIGL in Q3 2024 and held it in 1 quarter. The position peaked at $32 in Q3 2024. 122 funds tracked by Wall St. Rank hold RIGL as of Q4 2024.

  • Capital Performance Advisors reported no remaining Rigel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 2 Rigel Pharmaceuticals shares in Q4 2024, an estimated $32.
  • Capital Performance Advisors first reported a position in Rigel Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Rigel Pharmaceuticals position peaked at $32 in Q3 2024.
  • 122 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.